News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
234,257 Results
Type
Article (5131)
Company Profile (24)
Press Release (229102)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82675)
Career Advice (463)
Deals (15134)
Drug Delivery (8)
Drug Development (19408)
Employer Resources (30)
FDA (3750)
Job Trends (4008)
News (121145)
Policy (7623)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (294)
Accelerated approval (7)
Adcomms (4)
Allergies (16)
Alliances (14935)
ALS (38)
Alzheimer's disease (295)
Antibody-drug conjugate (ADC) (42)
Approvals (3859)
Artificial intelligence (80)
Autoimmune disease (28)
Automation (6)
Bankruptcy (97)
Best Places to Work (2968)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (115)
Cancer (955)
Cardiovascular disease (61)
Career advice (395)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (166)
Cervical cancer (5)
Clinical research (16998)
Collaboration (357)
Compensation (399)
Complete response letters (8)
COVID-19 (314)
CRISPR (13)
C-suite (340)
Cystic fibrosis (28)
Data (1402)
Denatured (1)
Depression (21)
Diabetes (78)
Diagnostics (2120)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (31)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (35)
Earnings (42942)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39607)
Executive appointments (429)
FDA (4505)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (345)
Gene editing (24)
Generative AI (5)
Gene therapy (103)
GLP-1 (149)
Government (429)
Guidances (197)
Healthcare (5076)
HIV (11)
Huntington's disease (5)
IgA nephropathy (17)
Immunology and inflammation (40)
Immuno-oncology (7)
Indications (17)
Infectious disease (340)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (32)
Interviews (53)
IPO (7919)
IRA (3)
Job creations (1126)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (106)
Leadership (5)
Legal (2358)
Liver cancer (22)
Longevity (2)
Lung cancer (103)
Lymphoma (86)
Machine learning (3)
Management (10)
Manufacturing (139)
MASH (50)
Medical device (3945)
Medtech (3955)
Mergers & acquisitions (7624)
Metabolic disorders (218)
Multiple sclerosis (19)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (542)
NextGen: Class of 2026 (1679)
Non-profit (737)
Now hiring (5)
Obesity (88)
Opinion (32)
Ovarian cancer (28)
Pain (26)
Pancreatic cancer (38)
Parkinson's disease (51)
Partnered (6)
Patents (51)
Patient recruitment (96)
Peanut (6)
People (25307)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (5108)
Phase 2 (7330)
Phase 3 (5905)
Pipeline (1994)
Policy (17)
Postmarket research (632)
Preclinical (1989)
Press Release (66)
Prostate cancer (64)
Psychedelics (3)
Radiopharmaceuticals (111)
Rare diseases (181)
Real estate (1902)
Recruiting (8)
Regulatory (5649)
Reports (17)
Research institute (314)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (53)
Series B (54)
Sickle cell disease (11)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (6)
Startups (1024)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (80)
Venture capital (9)
Weight loss (32)
Women's health (6)
Date
Last 7 days (150)
Last 30 days (544)
Last 365 days (9068)
2026 (798)
2025 (9223)
2024 (11217)
2023 (13374)
2022 (18820)
2021 (19831)
2020 (18379)
2019 (13300)
2018 (10266)
2017 (10089)
2016 (9253)
2015 (12249)
2014 (9695)
2013 (7831)
2012 (8408)
2011 (8873)
2010 (8705)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (76)
Arkansas (1)
Asia (11988)
Australia (1728)
California (3615)
Canada (1143)
China (186)
Colorado (145)
Connecticut (163)
Delaware (72)
Europe (25634)
Florida (542)
Georgia (67)
Idaho (24)
Illinois (164)
India (14)
Indiana (120)
Iowa (10)
Japan (168)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (382)
Massachusetts (2817)
Michigan (104)
Minnesota (201)
Mississippi (1)
Missouri (31)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1027)
New Mexico (5)
New York (827)
North Carolina (538)
North Dakota (4)
Northern California (1904)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (598)
Puerto Rico (1)
Rhode Island (19)
South America (283)
South Carolina (17)
Southern California (1324)
Tennessee (62)
Texas (481)
United States (12578)
Utah (111)
Virginia (84)
Washington D.C. (17)
Washington State (320)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
234,257 Results for "bcr corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
December 8, 2025
·
4 min read
Press Releases
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
May 15, 2025
·
7 min read
Business
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Ascentage Pharma (6855 HK) announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.
June 14, 2024
·
5 min read
Business
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.
June 14, 2024
·
8 min read
Press Releases
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engineering and Development for Drug Discovery Applications
December 12, 2024
·
3 min read
Biotech Bay
Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR Kits for Sensitive Immune Repertoire Profiling
Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR kits.
November 16, 2023
·
3 min read
Biotech Bay
Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Controls to Ensure Consistent Quality and Optimal Performance of TCR and BCR Profiling Assays
Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Premixed Controls, the first commercially available collection of synthetic mRNA constructs that can serve as universal controls for commercial or home-brewed AIR repertoire sequencing (AIR-Seq, TCR-seq and BCR-seq) assays based on multiplex RT-PCR or 5' RACE PCR techniques.
April 4, 2024
·
3 min read
Pharm Country
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Specialty cancer diagnostics company Precipio, Inc., announces the launch of its new quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market.
August 8, 2023
·
5 min read
Press Releases
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 10, 2025
·
9 min read
Genetown
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
Theseus Pharmaceuticals, Inc. announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor targeting BCR-ABL for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
January 5, 2023
·
9 min read
1 of 23,426
Next